Timing between public safety signals and label strengthening in targeted oncology therapies
European Journal of Clinical Pharmacology · 2026-11 · 82 (11)
DOI: 10.1007/s00228-026-04208-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 23.10.2026. Verfasst von Xiaogao Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. zxg_gcp@126.com. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Drug Labeling, Antineoplastic Agents, Molecular Targeted Therapy. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. zxg_gcp@126.com.
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Zitieren
APA
Zhang, X., Wang, X., & Wang, J. (2026). Timing between public safety signals and label strengthening in targeted oncology therapies. European Journal of Clinical Pharmacology, 82(11). https://doi.org/10.1007/s00228-026-04208-2
Vancouver
Zhang X, Wang X, Wang J. Timing between public safety signals and label strengthening in targeted oncology therapies. European Journal of Clinical Pharmacology. 2026;82(11). doi:10.1007/s00228-026-04208-2
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaogao and Wang, Xiaoyun and Wang, Jie},
title = {Timing between public safety signals and label strengthening in targeted oncology therapies},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
volume = {82},
number = {11},
doi = {10.1007/s00228-026-04208-2}
}
EUVIMED